Tuesday, April 15, 2014 10:11:07 PM
John Hargrove was brought on as a board member in September of 2010 when Amadeus was still being developed. Then in February of 2012, Titan inked the deal with Columbia University for the IREP, and put the Amadeus on the back burner. So in some respects, this is his baby too IMO.
I agree, trying to figure out his endgame is a challenge, but I do believe his 30+ years of experience and connections at Ethicon, Ethicon Endo-Surgery and Johnson & Johnson Health Care Systems, will benefit us tremendously, as he knows the process's and people from the inside out. Not dumb luck that he is part of our seasoned team. Heck, he probably participated in several M&A decisions during his 30 tenure. Think he knows the soft underbelly?
I'm assuming he'll receive sufficient stock options for his expertise (maybe even some sort of brokerage fee with Titan if a sale is ultimately negotiated?)
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM